AstraZeneca's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively ...
A subsidiary of AstraZeneca Plc partly won its motion to dismiss a case accusing the pharmaceutical company of cornering the market for a blood disorder drug, after a federal judge tossed federal ...
On April 16, 2025, EmblemHealth, Inc. (“Emblem”) filed a class action suit in the District Court for the District of Massachusetts against Alexion Pharmaceuticals, Inc. and Alexion Pharma ...
A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder drug by blocking competitors that wanted to launch similar, less-expensive ...
AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris AstraZeneca's Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint alleging ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
The price you pay for Soliris may depend on factors such as whether you have health insurance. Financial assistance may be available to help you with the cost of Soliris. your treatment plan your ...
Eculizumab is now approved for pediatric patients with gMG, expanding treatment options for this population. The monoclonal antibody targets the complement system, preventing tissue damage in gMG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results